76259-00-2

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,5-a]pyridine-3(2H)-thione is utilized as a lead compound for the development of new drugs due to its antiviral, antibacterial, and anticancer properties. Its diverse biological activities make it a promising candidate for creating therapeutic agents that can target a range of diseases and conditions.
Used in Drug Discovery:
In the field of drug discovery, Imidazo[1,5-a]pyridine-3(2H)-thione serves as a chemical scaffold that can be modified and optimized to enhance its therapeutic potential. Researchers can use Imidazo[1,5-a]pyridine-3(2H)-thione as a starting point to design new molecules with improved efficacy, selectivity, and safety profiles for various medical applications.
Used in Antiviral Applications:
Imidazo[1,5-a]pyridine-3(2H)-thione is used as an antiviral agent to combat viral infections. Its antiviral properties make it a candidate for developing treatments that can inhibit the replication and spread of viruses, potentially leading to new antiviral therapies.
Used in Antibacterial Applications:
As an antibacterial agent, Imidazo[1,5-a]pyridine-3(2H)-thione is employed to fight against bacterial infections. Its ability to target and eliminate bacteria makes it a potential component in the development of new antibiotics to address the growing issue of antibiotic resistance.
Used in Anticancer Applications:
Imidazo[1,5-a]pyridine-3(2H)-thione is used as an anticancer agent in the development of treatments for various types of cancer. Its potential to inhibit cancer cell growth and proliferation makes it a valuable compound in the search for new cancer therapies.

InChI:InChI=1/C7H6N2S/c10-7-8-5-6-3-1-2-4-9(6)7/h1-5H,(H,8,10)

Upstream product

• 3731-51-9 2-(Aminomethyl)pyridine 
• 103-72-0 phenyl isothiocyanate 
• 75160-54-2 N-phenyl-N'-(pyridin-2-ylmethyl)thiourea 

Downstream Products

• 141463-19-6 [(1S,2R)-1-Cyclohexylmethyl-2-hydroxy-3-(imidazo[1,5-a]pyridin-3-ylsulfanyl)-propyl]-carbamic acid tert-butyl ester 
• 76292-67-6 ethyl imidazo [1,5-a]pyridine-5-carboxylate 
• 76266-09-6 imidazo[1,5-a]pyridin-5-yl(phenyl)methanol 
• 76292-66-5 Imidazo[1,5-a]pyridin-5-yl-diphenyl-methanol 
• 76298-76-5 (3-Ethylsulfanyl-imidazo[1,5-a]pyridin-5-yl)-phenyl-methanol 
• 6558-64-1 5-methylimidazo<1,5-a>pyridine 
• 76259-03-5 (nitro-4 benzyl)thio-3 imidazo<1,5-a>pyridine 
• 345218-31-7 1-Methyl-5-phenyl-4-pyridin-2-yl-imidazolidine-2-thione 
• 80311-59-7 1-(4-Methoxy-phenyl)-5,5-dimethyl-4-pyridin-2-yl-imidazolidine-2-thione 
• 76259-02-4 (chloro-4 benzyl)thio-3 imidazo<1,5-a>pyridine 
• 80311-52-0 5,5-Dimethyl-1-phenyl-4-pyridin-2-yl-imidazolidine-2-thione 
• 80311-60-0 1-Benzyl-5,5-dimethyl-4-pyridin-2-yl-imidazolidine-2-thione 

Relevant academic research and scientific papers

CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

N-Heterocyclic carbenes derived from imidazo-[1,5-a]pyridines related to natural products: synthesis, structure and potential biological activity of some corresponding gold(I) and silver(I) complexes

A series of Au(I) complexes (12, 13, 14, 15, 16) and Ag(I) complexes (17, 18, 19, 20) derived from imidazo[1,5-a]pyridin-3-ylidenes were synthesized from AuCl(SMe2) or by reacting silver(I) acetate with 2,5-dimethylimidazo[1,5-a]pyridin-2-ium iodide or imidazo[1,5-a]pyridin-2-ium salts, and were characterized using NMR spectroscopy, mass spectrometry and elemental analyses. In addition, the Au(I) complex 13 and the Ag(I) complex 19 were characterized using single-crystal X-ray diffraction. Using paclitaxel as a standard, all Au(I) and Ag(I) N-heterocyclic carbene complexes were evaluated for their in vitro anti-tumour activity against 12 cell lines using a monolayer cell survival and proliferation assay. The highest anticancer activity was found for complexes 15, 13 and 14 with mean IC50 values of 10.09, 10.42 and 12.28?μM, respectively. Copyright

IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES

Compounds of the formula (I) provide pharmacological agents which are inhibitors of the P450 enzyme, aldosterone synthase, and thus may be employed for the treatment of aldosterone mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention, delay of progression, or treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Preferred are the compounds of formula (I) which are selective inhibitors of aldosterone synthase devoid of undesirable side effects due to general inhibition of cytochrome P450 enzymes.

Azines polycycliques. (IV). Synthese de derives sulfures en -3 de l'imidazolpyridine

La dihydro-2,3 imidazopyridinethione-3 est -preparee aisement a partir de l'aminomethyl-2 pyridine et est ensuite S-alkylee ou -aralkylee.On decrit, dans le cas du derive 3-thiomethyle, la trifluoroacetylation en -1, l'oxydation en methylsulfone et